ENDO 2013

STATEMENT OF INDEPENDENCE

The scientific content of the ENDO 2013 Session Recordings were developed by The Endocrine Society's Annual Meeting Steering Committee, independent of and prior to the solicitation of grant support. As a provider of independent and continuing medical education (CME) accredited by the Accreditation Council for Continuing Medical Education, The Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous.
While the ENDO 2013 Session Recordings do not offer AMA PRA Category 1 Credits™, its content was developed, in accordance with the ACCME's Essential Areas and Elements, including the Standards for Commercial Support. The commercial supporters of this meeting have no influence over topics or speakers. Educational grants support the production costs of the overall activity and are not used to compensate speakers in supported sessions.

ACKNOWLEDGEMENT OF COMMERICAL SUPPORT

The ENDO 2013 Session Recordings received no commercial support.

DISCLAIMER

The information presented in this activity represents the opinion of the faculty and is not necessarily the official position of The Endocrine Society.

LEARNING OBJECTIVES

Upon completion of this educational activity, learners will be able to:
  • Discuss state-of-the-art research in endocrinology
  • Demonstrate updated knowledge of the pathophysiology, diagnosis, and treatment of diabetes, obesity, cardiovascular disease, dyslipidemia, and adrenal, metabolic, bone, pediatric, pituitary, thyroid, and reproductive endocrine disorders
  • Practice updated clinical skills for more effective diagnosis, management, and treatment of endocrine disorders and related sequelae
  • Apply updated knowledge and clinical skills in improving patient care

TARGET AUDIENCE

This continuing medical education activity should be of substantial interest to endocrinologists, pediatric endocrinologists, internists, and all other clinical professionals who treat endocrine disorders.

DISCLOSURE POLICY

The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to The Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion. The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.
The following AMSC committee members reported relevant financial relationships: Cornier, M-A: Speaker, Merck. Deal, CL: Medical Advisory Board Member, Eli Lilly and Company; Consultant, Pfizer, Inc., Roche, Sandoz, Versartis, Eli Lilly and Company; Clinical Researcher, Eli Lilly and Company; Pfizer, Inc., Sandoz, Serono; Study Investigator, Eli Lilly and Company, Serono. Favus, M J: Consultant, CVS/Caremark. Fuleihan, G E-H: Grant Recipient, Servier Laboratories, Novartis. Ghizzoni, L: Lecturer, IPSEN. Grossman, A: Advisory Board Member, Lecturer, Novartis, IPSEN. Hollenberg, AN: Consultant, Amgen. Marks, DL: Consultant, BiolineRx, Inc., Tensive Controls, Inc. Millar, RP: Consultant, Euroscreen. Newell-Price, JD: Research Support and Honoraria, Novartis, IPSEN, HRA Pharma. Poutanen, M: Research Funding, Orion Pharma, Hormos Medical. Puigserver, P: Stockholder, GSK; Consultant, EMBER. Rayfield, EJ: Speakers Bureau, Abbott, Amylin, Eli Lilly, Sanofi-Aventis, Merck. Roberts, CT, Jr: Grantee, Investigator-Initiated Merck & Company; VP, Chief Science Officer, DiabetOmics, Inc. Smith, CL: Grantee and Scientific Advisory Board, Pfizer Inc. Tindall, DJ: Consultant, Medivation, Kearney Venture Partners; Research Grant Recipient, Consultant, Millennium. Tschöp, M: Consultant, Roche Pharmaceuticals. Tuttle, RM: Consultant, Genzyme Corporation, NovoNordisk, Veracyte. Wu, FC: Consultant, Eli Lilly & Company, Novartis Pharmaceuticals, Galapagos NV. Zeitler, P: Consultant, Daichii-Sankyo, BMS.
The following AMSC committee members reported no relevant financial relationships: Arlt, W; Brent, G; Calvi, LM; Elizalde, P; Gaddy, D; Grüters-Kieslich, A; Gutierrez-Hartmann, A; Handa, RJ; Low, MJ; McCartney, CR; Moenter, SM; Robins, D; Sasano, H; Segaloff, DL; Simonson, DC; Sladek, FM; Visser, JA; Yao, H H-C
Endocrine Society staff associated with the development of content for this activity reported no relevant financial relationships.

POLICY ON UNLABELED/OFF-LABEL USAGE

The Endocrine Society has determined that disclosure of unlabeled/off-label or investigational use of commercial product(s) is informative for audiences and therefore requires this information to be disclosed to the learners at the beginning of the presentation. Uses of specific therapeutic agents, devices, and other products discussed in this educational activity may not be the same as those indicated in product labeling approved by the Food and Drug Administration (FDA). The Endocrine Society requires that any discussions of such off-label use be based on scientific research that conforms to generally accepted standards of experimental design, data collection, and data analysis. Before recommending or prescribing any therapeutic agent or device, learners should review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse events.

PRIVACY & CONFIDENTIALITY STATEMENT

No individual performance data or any other personal information collected will be shared with third parties.

AMA PRA CATEGORY 1 CREDIT™ (CME) INFORMATION

This series of webcasts is not available for credit.
ACTIVITY RELEASE DATE: July, 2013

METHOD OF PARTICIPATION & SYSTEM REQUIREMENTS

This enduring material is presented in an online/computer-based format.

SYSTEM REQUIREMENTS

Your system must meet the following requirements:
Computer: with minimum processor and memory as recommended by operating system manufacturer
Operating System: Windows: XP, Vista, 7. Macintosh OSX
Internet Browser: consult the detailed system requirements page to determine the browser version required by Adobe Flash on your computer’s operating system.
Players & Plugins: Adobe Flash Player 10 or higher
Audio: Functioning sound card with attached speakers installed
Internet Connection: a broadband Internet connection
Please review the detailed system requirements page for more information and troubleshooting steps.
For technical assistance or information, please contact support@endosessions.org.
For questions about content, please contact The Endocrine Society at 301.941.0200 or education@endo-society.org.